CYTOKINETICS INC Q4 FY2024 earnings call

Regulatory Progress - Aficamten made major strides with NDA accepted by FDA, MAA validated by EMA, and NDA accepted by NMPA in China with priority review. PDUFA date is September 26, 2025. - Engaging in parallel regulatory interactions for Europe and China. ### Commercial Readiness - In US, commercial readiness activities peak with sales force recruitment and patient support program development. In Europe, hiring key leadership and preparing reimbursement strategies. ### Partnerships - Sanofi acquired rights to develop and commercialize aficamten in China; Bayer licensed aficamten in Japan. ### Clinical Trials - MAPLE-HCM to share top-line results in Q2 2025; COMET-HF (omecamtiv) and AMBER-HFpEF (CK-586) started. - FOREST-HCM has over 400 patients enrolled, with long-term safety data supporting aficamten's profile.

In the fourth quarter of 2024, revenues were $16.9 million compared to $1.7 million in the same period of 2023. Full year 2024 revenues were $18.5 million versus $7.5 million in 2023. R&D expenses for Q4 2024 were $93.6 million vs $85 million in 2023, and full year R&D expenses were $339.4 million vs $330.1 million. G&A expenses for Q4 2024 were $62.3 million vs $44.1 million in 2023, and full year G&A expenses were $215.3 million vs $173.6 million. The revenue growth was driven by upfront payments related to aficamten partnerships, while expenses increased due to clinical trial advancements and personnel costs.

2025 Guidance - GAAP operating expense (R&D + SG&A) expected to be between $670 million and $710 million. - Stock-based compensation included in GAAP operating expense expected to be between $110 million and $120 million. - Capital allocation focused on preparing for US commercial launch of aficamten, advancing pipeline trials, and investing in muscle biology platform. Anticipated growth in operating expense driven by commercial readiness for aficamten launch.

Regulatory Uncertainties - Delays or issues in FDA, EMA, or NMPA reviews could impact approval timelines. ### Competition - Other companies developing similar therapies could impact market share. ### Execution Risks - Challenges in commercial launch readiness, including sales force recruitment and payer negotiations may affect timelines.

Q: What's the timeline for label expansion of aficamten if MAPLE-HCM is positive?

A: Fady Malik mentioned it could come into 2026. Andrew Callos noted it would offer confirmatory evidence for physicians.

Q: How does HCM diagnosis rate change with CMI education?

A: Andrew Callos stated diagnosis rates could increase as guidelines adjust, studies are published, and education increases, potentially reaching 50% in 3-5 years.

Q: Thoughts on Edgewise dataset and REMS for aficamten?

A: Robert Blum and Fady Malik noted it's early to comment on another company's data, but emphasized aficamten's safety and efficacy data supports its profile.

Q: Differentiation of aficamten vs Camzyos in terms of pharmacogenomics?

A: Fady Malik said physicians recognize aficamten's fewer drug interactions and no 2C19 dependence, with no anticipated pharmacy monitoring issues.

Q: Endpoints in ACACIA-HCM and comparison to ODYSSEY?

A: Fady Malik explained ACACIA-HCM has KCCQ as primary and exercise as secondary, similar to ODYSSEY's dual primary approach, focusing on patient-reported outcomes and functional metrics.

Q: Patient population in MAPLE-HCM vs SEQUOIA?

A: Stuart Kupfer noted SEQUOIA's threshold less than 90% predicted didn't significantly differ in exercise capacity deficit from MAPLE-HCM's population with less than 100% predicted.

Q: BD and corporate development goals?

A: Isaac Ciechanover mentioned actively seeking external collaborations to augment R&D pipeline, focusing on complementary therapies and new modalities while maintaining focus on muscle biology expertise.

Q: COMET-HF enrollment and GALACTIC comparison?

A: Stuart Kupfer said enrollment in COMET-HF is proceeding as estimated, leveraging learnings from GALACTIC.

Q: CK-586 HFpEF study details?

A: Stuart Kupfer explained the study is flexible, enrolling first two cohorts by end 2025, evaluating safety, biomarkers, and pharmacokinetics.

Q: China market and Sanofi's work?

A: Isaac Ciechanover noted Sanofi's active involvement in China, with milestones tied to approval, and Sung Lee mentioned potential near-term milestones.

Q: FOREST-HCM protocol amendments and safety?

A: Fady Malik said protocol amendment on ECHO monitoring has limited data accumulated, with no additional amendments planned, and aficamten's safety profile remains strong.